SCHEMBL14903326

SCHEMBL14903326

O=C(CC(Cc1c[nH]c2ccccc12)NC(=O)C1CCCN1)NC(Cc1ccccc1)C(=O)N1CCCC1C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ DPP3 Q9NY33 2/20 0.49
▸ OPRM1 P35372 1/20 0.47
▸ GHSR Q92847 5/20 0.47
▸ ACE P12821 4/20 0.45
▸ ACE2 Q9BYF1 4/20 0.45
▸ TACR1 P25103 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14906478 0.97 DPP3 (0.49) DPP3OPRM1GHSR
SCHEMBL14906600 0.97 DPP3 (0.49) DPP3OPRM1GHSR
SCHEMBL6882312 0.90 ACE (0.52) ACEACE2
SCHEMBL14903342 0.90 ACE (0.52) ACEACE2
SCHEMBL6879092 0.90 ACE (0.52) ACEACE2
SCHEMBL6879217 0.90 ACE (0.52) ACEACE2
SCHEMBL14906462 0.90 ACE (0.52) ACEACE2
SCHEMBL6877609 0.90 ACE (0.52) ACEACE2
SCHEMBL14906597 0.90 ACE (0.52) ACEACE2
SCHEMBL30051517 0.89 GHSR (0.53) DPP3GHSRTACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10238713-B2 Cyclic tetrapeptides and therapeutic applications thereof LODZ UNIVERSITY OF TECHNOLOGY (PL) 2019-03-26 — — US disclosed
US-20170157204-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF LODZ UNIVERSITY OF TECHNOLOGY (PL) 2017-06-08 — — US disclosed
US-20170157204-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF LODZ UNIVERSITY OF TECHNOLOGY (PL) 2017-06-08 — — US disclosed
US-9382292-B2 Cyclic tetrapeptides and therapeutic applications thereof PEPTADERM SP. Z O.O. (PL) 2016-07-05 — — US disclosed
US-9382292-B2 Cyclic tetrapeptides and therapeutic applications thereof PEPTADERM SP. Z O.O. (PL) 2016-07-05 — — US disclosed
US-20130108655-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF PEPTADERM SP. Z O.O. (PL) 2013-05-02 — — US disclosed
US-20130108655-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF PEPTADERM SP. Z O.O. (PL) 2013-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170157204-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF PNISR, APLNR, VIP DPP3 300/4885OPRM1 1275/4885GHSR 451/4885
US-20130108655-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF PNISR, APLNR, VIP DPP3 300/4885OPRM1 1275/4885GHSR 451/4885
US-10238713-B2 Cyclic tetrapeptides and therapeutic applications thereof PNISR, APLNR, VIP DPP3 300/4885OPRM1 1275/4885GHSR 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback